NEFH and myeloid sarcoma: Serum NfL is a more desirable biomarker than CSF.Being less invasive, serum NlL has gained traction as the technology has improved.28 Although NfH might be a better measure than NfL in progressive MS, there is a scarcity of contemporary studies focusing on NfH in this condition.